Skip to main content
Clinical Trials/NCT04885075
NCT04885075
Unknown
Phase 4

A Randomized Controlled Trial Comparing the Efficacy of Intranasal Midazolam and Conventional Treatment With Intravenous Diazepam for Control of Seizures in Children

Shaheed Zulfiqar Ali Bhutto Medical University0 sites60 target enrollmentMay 30, 2021

Overview

Phase
Phase 4
Intervention
IV diazepam
Conditions
Seizures
Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
Enrollment
60
Primary Endpoint
Time taken for seizures to be controlled
Last Updated
4 years ago

Overview

Brief Summary

After approval , study will be conducted at the Children Hospital PIMS, Islamabad. Children 1-12 years presenting/admitted with seizures will be enrolled in the study after taking informed consent from the parents. Children's name, age, sex will be recorded by the on duty doctor. Patients will be randomly allocated to two equal groups. Group A (GA) will receive single dose of intravenous diazepam (0.2mg/kg/dose)after passing cannula, while Group B (GB) will receive single dose of intranasal midazolam (0.2mg/kg/dose).Response to treatment will be assessed by recording the time required for termination of seizures in both gruops.the time required for gaining intravenous accessin Group A will be recorded as well. Data will be collected through a structured performa.

Detailed Description

Benzodiazepines are the first line of drugs for cessation of acute seizures.benzodizepines can be given intravenous,orally,per rectal and intranasal.Conventional treatment of acute seizures is intravenous diazepam in most hospital settings which requires an IV access,which is not possible for parents to give at home.The main problem in an actively seizuring child is to reach the hospital and maintaining an intravenous line.Midazolam is a water soluble benzodiazepine which is widely used as an anxiolytic and anticonvulsant ,can be given through intravenously,intramuscularly, oral,buccal and nasal mucosa as well.it becomes lipid soluble at physiologic PH levels and reaches the CNS with a rapid onset and shorter duration of action.It is administered into nostril in a way that it comes into direct contact with nasal mucosa.It is given in a dose of 0.2mg\\kg and within a few minutes its level in serum are comparable to the injectables levels.It is a safe,cheap,easy to use and effective alternative to diazepam for use at home as well as in hospital settings.

Registry
clinicaltrials.gov
Start Date
May 30, 2021
End Date
November 30, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Nighat Haider

assistant professor of paediatrics

Shaheed Zulfiqar Ali Bhutto Medical University

Eligibility Criteria

Inclusion Criteria

  • Children 1-10 years both male and female visiting/admitted in Children Hospital PIMS with acute episode of seizure (febrile or afebrile)

Exclusion Criteria

  • Children requiring emergency resuscitation
  • Children with uncontrolled epilepsy

Arms & Interventions

Intravenous Diazepam

Intravenous diazepam (0.2mg/kg/dose) single dose stat

Intervention: IV diazepam

Intranasal Midazolam

Intranasal midazolam (0.2mg/kg/dose) single dose stat

Intervention: I/N Midazolam

Outcomes

Primary Outcomes

Time taken for seizures to be controlled

Time Frame: From administration of drug to the cessation of seizures up to 10 minutes

Intranasal midazolam will take less time for cessation of seizure than intravenous diazepam

Similar Trials